Form 4: Pfizer EVP McDermott Adjusts Equity Holdings

Pfizer Executive Vice President Michael McDermott reported a series of equity transactions, including the earn-out of stock appreciation rights and subsequent share dispositions for tax and exercise costs.

Summary

• Michael McDermott, Executive Vice President of Pfizer Inc. (PFE), reported changes in his beneficial ownership of common stock.
• On February 25, 2026, McDermott acquired 37,925 shares of common stock at an exercise price of $33.82 through the earn-out of stock appreciation rights (SARs), including dividend equivalents.
• Concurrently on February 25, 2026, he disposed of 679 shares at $27.09 to satisfy tax obligations related to the SAR earn-out.
• Also on February 25, 2026, 36,044 shares were disposed of at $26.92 to cover the exercise price of the SARs, with the price based on a 20-day average of closing prices.
• On February 26, 2026, an additional 3,503 shares were disposed of at $27.10 to satisfy tax obligations upon the vesting of restricted stock units (RSUs), including dividend equivalents.
• Following these transactions, McDermott's direct beneficial ownership of Pfizer common stock stands at 74,308 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It details routine executive compensation-related transactions and does not provide new information regarding Pfizer's operational performance or strategic direction.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that these types of insider transactions, involving the exercise of equity awards and subsequent sales to cover taxes and exercise costs, are routine events in executive compensation across various industries. They typically reflect the planned monetization of long-term incentive awards rather than a discretionary investment decision based on new company information.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine compensation-related transactions by an executive, not indicative of a change in company fundamentals or a significant shift in insider sentiment.
• Employees: No direct impact.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, specifically the exercise of stock appreciation rights and the vesting of restricted stock units, followed by dispositions to cover taxes and exercise costs. Such transactions are common and do not typically reflect a change in the company's fundamental outlook or strategic direction. Therefore, a seasoned investor would likely maintain their current position, as this filing provides no new information to warrant a change in investment thesis for Pfizer.

Keywords

Pfizer, PFE, insider transaction, Form 4, stock appreciation rights, restricted stock units, executive compensation, equity holdings